These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 38923758)

  • 1. Obesity enhances the response to neoadjuvant anti-PD1 therapy in oral tongue squamous cell carcinoma.
    Tan X; Li G; Deng H; Xiao G; Wang Y; Zhang C; Chen Y
    Cancer Med; 2024 Jun; 13(12):e7346. PubMed ID: 38923758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of the immune profile of oral tongue squamous cell carcinomas with advancing disease.
    Meehan K; Leslie C; Lucas M; Jacques A; Mirzai B; Lim J; Bulsara M; Khan Y; Wong NC; Solomon B; Sader C; Friedland P; Mir Arnau G; Semple T; Lim AM
    Cancer Med; 2020 Jul; 9(13):4791-4807. PubMed ID: 32383556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apatinib potentiates the therapeutic effect of anti-PD-1 in locally advanced head and neck cancers.
    Liu S; Zhang L; Ye W; Zhou R; Gu Z; Shi C; Xu S; Li J; Zhang Z; Han Y
    Oral Dis; 2024 Jul; 30(5):2940-2951. PubMed ID: 37846172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Negative prognostic behaviour of PD-L1 expression in tongue and larynx squamous cell carcinoma and its significant predictive power in combination with PD-1 expression on TILs.
    Ahmadvand S; Norouzi LA; Mohammadi Y; Safaei A; Khademi B; Motiee-Langroudi M; Ghaderi A
    BMC Immunol; 2024 Jan; 25(1):7. PubMed ID: 38229027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting Dendritic Cell Dysfunction to Circumvent Anti-PD1 Resistance in Head and Neck Cancer.
    Saito S; Kono M; Nguyen HCB; Egloff AM; Messier C; Lizotte P; Paweletz C; Adkins D; Uppaluri R
    Clin Cancer Res; 2024 May; 30(9):1934-1944. PubMed ID: 38372707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complete response upon salvage chemotherapy after anti-PD1 failure: Watch and wait.
    Saleh K; Bellanger C; Garcia G; Classe M; Even C
    Eur J Cancer; 2021 Mar; 145():155-157. PubMed ID: 33476895
    [No Abstract]   [Full Text] [Related]  

  • 7. Immunohistochemical Study of PD-1/PD-L1 Axis Expression in Oral Tongue Squamous Cell Carcinomas: Effect of Neoadjuvant Chemotherapy on Local Recurrence.
    Naruse T; Yanamoto S; Okuyama K; Ohmori K; Tsuchihashi H; Furukawa K; Yamada SI; Umeda M
    Pathol Oncol Res; 2020 Apr; 26(2):735-742. PubMed ID: 30767115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of factors related to immunotherapy efficacy and prognosis in patients with advanced head and neck squamous cell carcinoma.
    Xu X; Li R; Zhang L; Zhu G; Ren D; Wu L; Gong X
    Diagn Pathol; 2021 Nov; 16(1):110. PubMed ID: 34823553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EphA8 is a Prognostic Factor for Oral Tongue Squamous Cell Carcinoma.
    Liu L; Wang X; Ge W
    Med Sci Monit; 2018 Oct; 24():7213-7222. PubMed ID: 30300334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular characterisation in tongue squamous cell carcinoma reveals key variants potentially linked to clinical outcomes.
    Alsofyani AA; Dallol A; Farraj SA; Alsiary RA; Samkari A; Alhaj-Hussain BT; Khan JA; Al-Maghrabi J; Al-Khayyat SS; Alkhatabi H; Elaimi A; Buhmeida A; Johargy AK; Abuzenadah AM; Azhar EI; Al-Qahtani MH
    Cancer Biomark; 2020; 28(2):213-220. PubMed ID: 32250288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor hypoxia is associated with resistance to PD-1 blockade in squamous cell carcinoma of the head and neck.
    Zandberg DP; Menk AV; Velez M; Normolle D; DePeaux K; Liu A; Ferris RL; Delgoffe GM
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma.
    Prat A; Navarro A; Paré L; Reguart N; Galván P; Pascual T; Martínez A; Nuciforo P; Comerma L; Alos L; Pardo N; Cedrés S; Fan C; Parker JS; Gaba L; Victoria I; Viñolas N; Vivancos A; Arance A; Felip E
    Cancer Res; 2017 Jul; 77(13):3540-3550. PubMed ID: 28487385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between pretreatment lymphocyte count and response to PD1 inhibitors in head and neck squamous cell carcinomas.
    Ho WJ; Yarchoan M; Hopkins A; Mehra R; Grossman S; Kang H
    J Immunother Cancer; 2018 Aug; 6(1):84. PubMed ID: 30170629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-L1 expression in tongue squamous cell carcinoma.
    Akisada N; Nishimoto K; Takao S; Gion Y; Marunaka H; Tachibana T; Makino T; Miki K; Akagi Y; Tsumura M; Toji T; Yoshino T; Nishizaki K; Orita Y; Sato Y
    Med Mol Morphol; 2021 Mar; 54(1):52-59. PubMed ID: 32699939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tertiary lymphoid structure-related score as a predictor for survival prognosis and immunotherapy response in head and neck squamous cell carcinoma.
    Wu F; Cao H; Ren S; Wu J; Liu X; Li Q; Xu Q; Chen J; Wang R; Chen S; Kuang S; Xia B; Li Y; Wang L; Li J; Li B; Li J; Lan T
    Front Immunol; 2024; 15():1483497. PubMed ID: 39493749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma.
    Leidner R; Crittenden M; Young K; Xiao H; Wu Y; Couey MA; Patel AA; Cheng AC; Watters AL; Bifulco C; Morris G; Rushforth L; Nemeth S; Urba WJ; Gough M; Bell RB
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of novel subtypes based on ssGSEA in immune-related prognostic signature for tongue squamous cell carcinoma.
    Jin Y; Wang Z; He D; Zhu Y; Chen X; Cao K
    Cancer Med; 2021 Dec; 10(23):8693-8707. PubMed ID: 34668665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel gene signature related to fatty acid metabolism predicts prognosis, immune landscape, and drug sensitivity in early-stage lung squamous cell carcinoma.
    Xu J; Yu M; Fan W; Feng J
    Transl Cancer Res; 2024 Feb; 13(2):525-541. PubMed ID: 38482436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor.
    Curti BD; Koguchi Y; Leidner RS; Rolig AS; Sturgill ER; Sun Z; Wu Y; Rajamanickam V; Bernard B; Hilgart-Martiszus I; Fountain CB; Morris G; Iwamoto N; Shimada T; Chang S; Traber PG; Zomer E; Horton JR; Shlevin H; Redmond WL
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33837055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Seven Immune-Related Genes' Prognostic Value and Correlation with Treatment Outcome in Head and Neck Squamous Cell Carcinoma.
    Mu R; Shen Y; Guo C; Zhang X; Yang H; Yang H
    Mediators Inflamm; 2023; 2023():8533476. PubMed ID: 39282247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.